Magnesium Trial in Acute Asthma: Pediatric Emergency Department Study Data

A randomized double-blind placebo-controlled trial conducted across 6 Canadian pediatric emergency departments. The study enrolled otherwise healthy children aged 2–17 years with acute asthma and a Pediatric Respiratory Assessment Measure (PRAM) score ≥5 after initial therapy. The dataset contains trial results for the primary outcome of PRAM score at 2 hours post-intervention and secondary outcomes including hospitalization and re-visits.

Use Cases

• Evaluate the efficacy of intravenous magnesium sulfate versus placebo based on PRAM score changes.
• Analyze hospitalization rates and 72-hour re-visit outcomes for pediatric asthma patients.
• Study the association between early IVMg therapy and improvement in respiratory distress over a 3-hour period.
• Compare vital sign changes between treatment and control groups in a pediatric emergency setting.

Strengths

• Data originates from a randomized double-blind placebo-controlled trial, a gold-standard study design.
• The trial was conducted across 6 pediatric emergency departments, providing a multi-site perspective.
• Sample size was calculated for 192 patients to achieve 80% power for detecting a PRAM score difference of ≥1.0 point.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description states 'No results generated yet,' indicating the dataset may contain protocol or placeholder data.

Provenance

Source

Suzanne Schuh via figshare.

Collection Method

Data collected as part of the 'Magnesium Trial in Acute Asthma in Emergency Department' randomized controlled trial.

Freshness

Last updated 2026-06-03 17:52:38; freshness should be verified.

Geography

6 pediatric emergency departments in Canada.